FreezeM, an agtech company focusing on Black Soldier Fly (BSF) protein production, secured $14.2 million in Series A funding to accelerate market expansion. Led by the European Innovation Council Fund, this investment empowers FreezeM to scale its “Breeding-as-a-Service” (BaaS) platform and commercialize its revolutionary PauseM® technology.
PauseM® tackles a critical hurdle in the BSF protein industry: breeding complexity. Traditionally, navigating colony instabilities and technological gaps requires extensive bio-expertise, hindering large-scale production. FreezeM’s solution offers “paused” BSF neonates with a 14-day shelf life and high survival rates, simplifying breeding and enabling a new decoupled production model. PauseM® eliminates breeding limitations, allowing BSF protein facilities to readily source neonates, boosting production efficiency and reducing costs.
“This funding enables us to globally embed our technology at scale and accelerate breeding hub growth in Europe and Israel, driving successful commercial expansion,” explained Dr. Yuval Gilad, Co-founder and CEO of FreezeM. “Our technology unlocks the potential of the insect market, propelling it towards fulfilling its true potential.”
FreezeM’s innovation plays a vital role not only in boosting insect protein production capacity for animal feed but also in promoting environmental sustainability. By leveraging BSF, FreezeM’s technology fosters a circular economy, reducing reliance on precious agricultural land and resource-intensive traditional protein sources.
With the Series A funding and PauseM® technology, FreezeM positions itself as a leader in revolutionizing the BSF protein industry. By addressing the breeding hurdle, they pave the way for efficient and scalable insect protein production, contributing to a more sustainable and secure food system.
